Exclusive: Lilly expects US Medicare to reverse course, fully cover Alzheimer’s drugs
Derek Asay, Lilly's SVP of Government Strategy and Federal Accounts, has expressed confidence to Reuters that the U.S. Medicare health plan will soon remove its strict coverage limits on new Alzheimer's drugs. This is due to the increasing evidence of the treatment's ability to reduce amyloid brain plaques and help patients. The agency's current plan would only require it to pay for the drug once it receives FDA approval if patients are part of a registry, which Lilly believes would create an unfairness in its use. This optimism from Lilly has not been previously discussed publicly, and the news has caused the company's shares to rise by 3% to $385.96 on Friday.0
